Published 3 days ago • loading... • Updated 2 days ago
Kazia Therapeutics Limited Announces Proposed Public Offering
Kazia said proceeds will fund paxalisib studies in breast cancer and other oncology indications, while Series A and B warrants hinge on future trial readouts.